NovoCure Ltd Earnings Per Share Disclosure
| Year ended December 31, | |||||||||||||||||
| 2025 | 2024 | 2023 | |||||||||||||||
| Net income (loss) attributable to ordinary shares as reported | $ | (136,227) | $ | (168,627) | $ | (207,043) | |||||||||||
| Net income (loss) used in computing basic net income (loss) per share | $ | (136,227) | $ | (168,627) | $ | (207,043) | |||||||||||
| Adjustment needed in calculating diluted net income (loss) per share | — | — | — | ||||||||||||||
| Net income (loss) used in computing diluted net income (loss) per share | $ | (136,227) | $ | (168,627) | $ | (207,043) | |||||||||||
Weighted average number of ordinary shares used in computing basic and diluted net income (loss) per share | 111,471,991 | 107,834,368 | 106,391,178 | ||||||||||||||
Potentially dilutive shares that were excluded from the computation of basic and diluted net income (loss) per share: | |||||||||||||||||
| Options | 9,297,875 | 9,558,506 | 6,950,781 | ||||||||||||||
RSUs and PSUs | 4,781,731 | 4,560,415 | 1,423,377 | ||||||||||||||
| ESPP | 208,854 | 222,451 | 161,627 | ||||||||||||||
| Weighted anti-dilutive shares outstanding which were not included in the diluted calculation | 14,288,460 | 14,341,372 | 8,535,785 | ||||||||||||||
Basic and diluted net income (loss) per ordinary share | $ | (1.22) | $ | (1.56) | $ | (1.95) | |||||||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Feb 26, 2026 | Showing above |
| 2024 | Feb 27, 2025 | |
| 2023 | Feb 22, 2024 | |
| 2022 | Feb 23, 2023 | |
About Earnings Per Share Disclosures
The earnings per share disclosure breaks down the calculation from net income to both basic and diluted EPS, revealing the full impact of a company's capital structure on per-share economics. The reconciliation between basic and diluted share counts exposes how many stock options, RSUs, convertible securities, and warrants are potentially dilutive to existing shareholders.
Key signals: a widening gap between basic and diluted shares indicates growing dilution from equity compensation or convertible instruments. Anti-dilutive securities excluded from the diluted calculation deserve attention — they represent latent dilution that will materialize if the stock price rises. Watch for the effect of share buybacks on per-share metrics: EPS growth driven primarily by repurchases rather than income growth signals weakening fundamentals. Compare year-over-year changes in the diluted share count against equity compensation expense to assess whether management is effectively managing dilution.